Wednesday 10 September 2008

Download James mp3






James
   

Artist: James: mp3 download


   Genre(s): 

Rock: Pop-Rock
Other

   







Discography:


Fresh As A Daisy-The Singles
   

 Fresh As A Daisy-The Singles

   Year: 2007   

Tracks: 20
Getting Away With It: Live (CD 2)
   

 Getting Away With It: Live (CD 2)

   Year: 2002   

Tracks: 10
Getting Away With It: Live (CD 1)
   

 Getting Away With It: Live (CD 1)

   Year: 2002   

Tracks: 12






As unrivalled of the number 1 groups to be dubbed "the following Smiths," James became an institution on the British alternative practice of medicine conniption of the '80s and '90s with their pleasant folk-pop. Early in their life history, James were blasted by congratulations from their god Morrissey, which off out to be both a benediction and a execration. The group was pegged as mediocre Smiths, yet continued to turn and book, eventually gaining a sizeable following. In the late '80s, the chemical group, like many of their British peers, became tortuous in the acidic house-inspired "loose-fitting" picture and recorded the baggy-inspired "Sit Down," which became their breakthrough strike. Shortly after "Sit Down," James became more than observational, culminating in a coaction with Brian Eno that resulted in their biggest American album, Laid, in 1993. James took quatern years to follow Laid, by which metre their hearing had returned to a cult following.


Henry James formed in Manchester in 1982, when Paul Gilbertson (guitar), Jim Glennie (bass), and Gavan Whelan (drums) met Tim Booth (vocals) at Manchester University and asked him to join their newcomer lot. During the next yr, the lot became regulars on the local order racing circuit, and by 1983, they had signed to Factory, cathartic their debut EP, Jimone, later that yr. Two days by and by, their second EP, James II, was released, and Morrissey, the lead isaac Merrit Singer of the Smiths, publically endorsed the chemical group, asking them to open for his group. By the summer of 1985, Larry Gott had replaced Gilbertson, and the group signed to Sire Records. Working with producer Lenny Kaye, the group recorded its debut, Stammer, that year, cathartic it in former 1986 to generally positive reviews.


Over the succeeding deuce age, James toured invariably, building up a solid fan understructure. They released their second gear album, the folky Strip mine, in 1988. The record failed to capitalise on their live following, and the ring gone Sire the following yr, signing with the main Rough Trade. On their new tag, James released the slightly successful "Sit Down" and the live album One Man Clapping, which climbed to numeral one on the indie charts. In 1990, Whelan was replaced by David Baynton-Power, and James expanded to a septet with the addition of keyboardist Mark Hunter, violinist Saul Davies, and trumpeter Andy Diagram. The new card signed to Fontana Records and released Gold Mother in the fall. Following a handful of pocket-size rack up singles, Gold Mother final became a breakthrough success in the spring of 1991, when a re-recorded edition of "Sit Down" -- today boast a present-day sloppy wash up -- climbed to number 2 on the U.K. charts and became a staple on U.S. advanced rock receiving set. Although the success of "Sit Down" was a blessing, it as well was a condemnation, as the single became all James were known for. The banding began to insurgent in concert, performing nearly zero only new material, and their following album, 1992's Seven, was sensed as a misguided thrust at swelled area rock.


For the followup to VII, James stripped away Diagram and worked with producer Brian Eno. The resulting record, Laid, was a quieter, more than ambitious album, and it standard some of the band's best reviews. While the album was unheeded in the U.K., it was an alternative rock rack up in the U.S. on the lastingness of the rubric cart track, which became a crossing over hit. During the Laid roger Sessions, James recorded another album's worth of experimental medicine with Eno that was released in the fall of 1994 as Wah Wah. The album received mixed reviews and the grouping took an extended split up throughout 1995, partly due to guitarist Gott's going away. In 1996, Tim Booth recorded a collaborationism with composer Angelo Badalamenti (Gemini Peaks, Blue Velvet) entitled Stall and the Bad Angel, which received more often than not incontrovertible reviews.


With guitar player Adrian Oxaal in tow, James returned in early 1997 with Lash, a more straightforward record that was greeted with interracial reviews. 1999's Millionaires, recorded with new guitarist Michael Kulas, was initially released only in the U.K. Their spectacular follow-up, 2001's Proud of to Meet You, was besides available solely in the U.K. A few months after, frontman Tim Booth announced his going away from the band he founded almost 20 eld before, citing that it was the right time to go. A winter tour of the U.K. was slated for December 2001, marking Booth's last with the band. The remaining members insisted they'd carry on; however, James formally called it quits at the tour's ending. In 2007, James announced that it would be re-forming and embarking on a tour in living of the double-disc digest Fresh as a Daisy: The Singles.





Tindersticks | Download mp3

Monday 11 August 2008

Mr. Freaky

Mr. Freaky   
Artist: Mr. Freaky

   Genre(s): 
Dance
   



Discography:


Mr. Freaky + Bonus Singles 'pr   
 Mr. Freaky + Bonus Singles 'pr

   Year: 1998   
Tracks: 12


One Hour And One   
 One Hour And One

   Year: 1988   
Tracks: 8




 






Wednesday 6 August 2008

Cadence Pharmaceuticals Announces FDA Concurrence With Clinical Development Plan For Acetavance(TM)

�Cadence Pharmaceuticals,
Inc. (Nasdaq: CADX) announced that it has received written direction
from the U.S. Food and Drug Administration (FDA) that one post-operative
pain trial (Sinatra Study) and one febricity trial (Study 302) are sufficient
to meet the pivotal clinical trial requirements for submission of a New
Drug Application (NDA) for Acetavance, the company's intravenous
formulation of tempra for the treatment of acute pain and fever in
adults and children. As previously reported, both the Sinatra Study and
Study 302 have already been completed with prescribed outcomes. Cadence is
non required nor does it currently be after to lead up any additional clinical
trials of Acetavance for NDA submission.





Upon the pass completion of on-going clinical trials evaluating paediatric
pharmacokinetics (Study 102), adult safety (Study 351), and pediatric
refuge (Study 352), the clinical development design, consistent with the
advice received from the FDA, will be complete. The company's abdominal
laparoscopic operation trial (Study 304) is not needed for compliance of
the Acetavance NDA. The company currently anticipates submitting the NDA in
the second quarter of 2009.





"We are very pleased with the result of our communications with the
FDA," stated Ted Schroeder, President and Chief Executive Officer of
Cadence. "With this clear steering, we tin now focus on complementary the
on-going development activities and preparing to submit the Acetavance NDA."



About Acetavance(TM)





Acetavance is a proprietorship intravenous formulation of phenaphen
for the treatment of acute pain in the neck and pyrexia. Cadence acquired the undivided
rights to Acetavance in the United States and Canada from Bristol-Myers
Squibb Company (BMS), which has marketed the product as Perfalgan(R)
throughout Europe and other parts of the world beginning in 2002. In 2007,
BMS sold approximately 80 million units in Europe, where it is the market
leading injectable anodyne in price of both dollars and units sold. In
the United States, injectable analgesics to treat acute pain, particularly
in the postoperative setting, ar currently limited to opioids and a
single not steroidal anti-inflammatory drug, both of which may be
associated with significant inauspicious side-effects. In placebo-controlled
clinical trials, Acetavance has demonstrated significant hurting relief,
improved patient satisfaction, and opioid-sparing potential with a guard
profile comparable to placebo.



About Cadence Pharmaceuticals, Inc.





Cadence Pharmaceuticals is a biopharmaceutical company focused on
in-licensing, developing and commercializing proprietorship product candidates
principally for use in the infirmary setting. The company presently has two
Phase III product candidates in development, Acetavance(TM) (endovenous
acetaminophen) for the treatment of acute pain and fever, and Omigard(TM)
(omiganan pentahydrochloride 1% topical gelatin) for the prevention of
catheter-related infections. For more information some Cadence's pipeline,
visit http://www.cadencepharm.com.



Forward Looking Statements





Statements included in this press dismissal that are not a description of
historical facts are innovative statements. Forward-looking statements
include statements regarding: the FDA's concurrence with Cadence's proposition
that, presumptuous positive results, the clinical development design will be
sufficient to serve as the footing for the company's submission of an NDA for
Acetavance(TM), and that no additional clinical trials volition be required;
the rendering of results of completed clinical trials of Acetavance;
and the timeframe in which Cadence anticipates submitting an NDA for
Acetavance. The comprehension of innovative statements should not be
regarded as a representation by Cadence that whatsoever of its plans will be
achieved. Actual results may take issue materially from those set forth in this
press release due to the risks and uncertainties inherent in the company's
business enterprise, including, without limitation: the FDA english hawthorn require Cadence to
finish additional clinical, non-clinical or other requirements prior to
the submission or the approval of an NDA for Acetavance; clinical trials of
Acetavance may bring out negative or inconclusive results, or may be
inconsistent with antecedently conducted clinical trials; the outcomes of
final analyses of information from the Acetavance clinical trials may vary from
the initial analyses, and the FDA may not agree with Cadence's
rendering of such results; the clinical trial data submitted with the
NDA for Acetavance may demonstrate inadequate therapeutic efficacy, or the
prevalence or severity of adverse side effects may be greater than
hoped-for; the company may live delays in completing important
pre-commercialization fabrication development activities for Acetavance,
such as the output of batches of the product requisite to perform
stability studies, and may be required to perform additional presymptomatic
or clinical testing as a resultant role of changes to the Acetavance manufacturing
process; the company crataegus laevigata require hearty additional financing to complete
its development program for Acetavance and, if sanctioned, to successfully
launch this product prospect, and it may not be able to rear sufficient
capital when required, or at all; and other risks detailed in Cadence's prior
press releases as well as in Cadence's periodical public filings with the
Securities and Exchange Commission.





You are cautioned not to position undue reliance on these forward-looking
statements, which speak only as of the date hereof. All forward-looking
statements are qualified in their integrality by this cautionary statement and
Cadence undertakes no obligation to revise or update this press press release to
ruminate events or circumstances later on the engagement hereof. This caution is made
under the safe harbor viands of Section 21E of the Private Securities
Litigation Reform Act of 1995.



Cadence(TM), Acetavance(TM) and Omigard(TM) ar trademarks of Cadence
Pharmaceuticals, Inc. Perfalgan(R) is a trademark of Bristol-Myers Squibb
Company.




Cadence Pharmaceuticals, Inc.


http://www.cadencepharm.com




More info

Friday 27 June 2008

Bone Brothers

Bone Brothers   
Artist: Bone Brothers

   Genre(s): 
Rap: Hip-Hop
   



Discography:


Bone Brothers 2   
 Bone Brothers 2

   Year: 2007   
Tracks: 17




With Bone Thugs-N-Harmony retention a low profile next their mid-'90s commercial tip, members of the Cleveland-born gangsta rap crew focussed on their solo careers. Bizzy Bone (natural Bryon Anthony McCane) became, in effect, the Ol' Dirty Bastard of the group, gaining more notoriety for his increasingly bizarre media appearances and self-admitted drug and alcohol problems than for solo albums like Public speaking in Tongues or Alpha and Omega. Although Bizzy Bone's erratic behavior had gotten him thrown out of Bone Thugs-N-Harmony on several occasions, bandmate Layzie Bone (Steven Howse) coupled forces with him in 2005 for the duo project The Bone Brothers, featuring the unmarried "Hip Hop Baby." Both members continued with their solo careers following this album, with Layzie Bone issue It's Not a Game later in 2005 and Bizzy Bone releasing Thugs Revenge in early 2006.





Johnny Depp - Surprise Guest Depp Steals The Show At The Mtv Movie Awards

Double P

Double P   
Artist: Double P

   Genre(s): 
Other
   



Discography:


Sex and Rum   
 Sex and Rum

   Year: 2004   
Tracks: 4




 





David Friedman

Manau

Manau   
Artist: Manau

   Genre(s): 
Rap: Hip-Hop
   



Discography:


On Peut Tous Rever   
 On Peut Tous Rever

   Year: 2004   
Tracks: 12


Panique Celtique   
 Panique Celtique

   Year: 1998   
Tracks: 11




 






Auli

Auli   
Artist: Auli

   Genre(s): 
Folk
   



Discography:


Sen Dzirdeeju   
 Sen Dzirdeeju

   Year: 2005   
Tracks: 12




 





Sarah Connor